HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

cremophor

RN given refers to cpd with unknown MF; see also records for cremophor EL & cremophor A; polyoxyethylated castor oil
Also Known As:
MGH 40; chremofore; cremophor AP; cremophor RH 40; cremophor RH 40-60; cremophor WO-CE 5070; cremophor, O(beta)-isomer; macrogloglycerol hydrostearate 40
Networked: 133 relevant articles (13 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Au, Jessie L-S: 4 articles (09/2015 - 11/2004)
2. Lu, Ze: 4 articles (09/2015 - 11/2004)
3. Wientjes, M Guillaume: 3 articles (09/2015 - 12/2013)
4. Tsai, Max: 3 articles (01/2014 - 11/2004)
5. Okada, Morihito: 2 articles (09/2021 - 04/2015)
6. Kang, Soon Beom: 2 articles (01/2018 - 05/2017)
7. Kim, Young Tae: 2 articles (01/2018 - 05/2017)
8. Fu, Fenghua: 2 articles (01/2014 - 02/2013)
9. Tian, Jingwei: 2 articles (01/2014 - 02/2013)
10. Wang, Hongbo: 2 articles (01/2014 - 02/2013)

Related Diseases

1. Neoplasms (Cancer)
2. Ovarian Neoplasms (Ovarian Cancer)
3. Breast Neoplasms (Breast Cancer)
4. Adenocarcinoma
07/01/2003 - "Mammary adenocarcinoma 16/c tumor-bearing mice were treated with an i.v. bolus of 11 mg/kg C-52 or 38 mg/kg C-55 in Cremophor-alcohol. "
04/01/2018 - "Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma."
09/01/2018 - "Patients with histologically proven advanced inoperable pancreatic adenocarcinoma (PDAC), treated with non-cremophor-based paclitaxel-gemcitabine combination (PG) (gemcitabine-nanoxel or gemcitabine-abraxane) between January 2012 and June 2015, were retrospectively analyzed. "
03/08/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "
5. Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2016 - "Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer."
09/01/2018 - "Non-cremophor-based paclitaxel in combination with gemcitabine appeared efficacious for advanced pancreatic cancers in routine clinical practice. "
09/01/2018 - "Gemcitabine combined with non-cremophor-based paclitaxel is one of the standards of care in advanced inoperable pancreatic cancer. "
09/01/2018 - "Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre."
03/08/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "

Related Drugs and Biologics

1. Paclitaxel (Taxol)
2. Albumin-Bound Paclitaxel
3. Micelles
4. Solutions
5. 130-nm albumin-bound paclitaxel
6. Albumins
7. Carboplatin (JM8)
8. Ethanol (Ethyl Alcohol)
9. 1-phenyl-3,3-dimethyltriazene (PDT)
10. Proteins (Proteins, Gene)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Therapeutics
3. Combination Drug Therapy (Combination Chemotherapy)
4. Intravenous Injections
5. Intravenous Administration